Applied Clinical Trials
Executives from Atlantic Research Group discuss the importance of CRAs in rare disease clinical trials.
Paul Bishop and Lyle Camblos
Advertisement
Paul Bishop is CEO, Atlantic Research Group (ARG), and can be reached at pbishop@atlanticresearchgroup.com Lyle Camblos is Managing Partner, Atlantic Research Group (ARG) and can be reached at lcamblos@atlanticresearchgroup.com
Articles by Paul Bishop and Lyle Camblos
Advertisement
Latest Updated Articles
- The Value of Empowered CRAs in Rare Disease Studies
August 2nd 2017
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The Design Flaws Trial Simulations Surface That Traditional Planning Misses
2
How AI Is Changing Endpoint Selection Before a Trial Even Starts
3
ACT Brief: AI Expands Endpoint Options, CRO Oversight Documentation, and Kidney Cancer Approval
4
Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It
5